Research programme: HIV Vpr-based cancer therapy - Inovio

Drug Profile

Research programme: HIV Vpr-based cancer therapy - Inovio

Alternative Names: VGX-100 - Inovio; VGX-150

Latest Information Update: 30 Apr 2012

Price : $50

At a glance

  • Originator VGX Pharmaceuticals
  • Class
  • Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Gastric cancer; Lymphoma; Malignant melanoma

Most Recent Events

  • 30 Apr 2012 Discontinued - Preclinical for Gastric cancer in USA (unspecified route)
  • 30 Apr 2012 Discontinued - Preclinical for Lymphoma in USA (unspecified route)
  • 30 Apr 2012 Discontinued - Preclinical for Malignant melanoma in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top